Neurocrine reports sustained benefits of INGREZZA for Huntington’s chorea

SAN DIEGO - Neurocrine Biosciences, Inc. (NASDAQ:NBIX), a $13.6 billion biopharmaceutical company with strong financial health according to InvestingPro metrics, presented new three-year data showing that INGREZZA (valbenazine) demonstrated sustained improvements in chorea severity among adults with Huntington’s disease, according to findings presented Monday at the 2025 MDS International Congress of Parkinson’s Disease and Movement Disorders in Honolulu.

The open-label KINECT-HD2 study, which included 154 adult participants who received once-daily INGREZZA for up to three years, showed early and maintained improvements in chorea, a debilitating symptom characterized by involuntary movements that can affect motor coordination, gait, swallowing and speech. This development comes as Neurocrine maintains impressive revenue growth of 18.4% over the last twelve months.

Data indicated robust improvements in chorea severity were observed by Week 2 at the lowest dose (40 mg), with benefits maintained through Week 156. Patient Global Impression of Change response rates improved from 34.5% at Week 2 to 77.8% at Week 156.

The study also found that concomitant use of antipsychotic medication had no apparent effect on chorea improvement.

INGREZZA was generally well tolerated during long-term treatment. The most common treatment-emergent adverse events were falls (42.9%), somnolence (25.3%) and fatigue (21.4%). Serious adverse events occurred in less than 2% of participants, while 15.6% discontinued due to adverse events.

"Most people with Huntington’s disease experience chorea, one of the most debilitating symptoms of the condition that can interfere with motor coordination, gait, swallowing and speech," said Sanjay Keswani, Chief Medical Officer at Neurocrine Biosciences, in the press release.

Huntington’s disease is a hereditary progressive neurodegenerative disorder affecting approximately 41,000 adults in the U.S., with more than 200,000 at risk of inheriting the disease.

INGREZZA is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor approved by the FDA for the treatment of adults with tardive dyskinesia and chorea associated with Huntington’s disease. The company’s stock has shown strong momentum with a 43% gain over the past six months. For detailed financial analysis and additional insights, investors can access comprehensive research reports on InvestingPro, which offers exclusive access to over 10 more ProTips and advanced valuation metrics for NBIX.

In other recent news, Neurocrine Biosciences has reported promising results for its medication INGREZZA in treating tardive dyskinesia. A post-hoc analysis from the Phase 4 KINECT-PRO study showed that 57.8% of patients achieved symptomatic remission after 24 weeks of treatment. In addition, Neurocrine Biosciences announced significant findings from its Phase 2 SAVITRI trial for the depression treatment osavampator, demonstrating statistically significant improvement in patients with major depressive disorder at a 1 mg dose. Following these developments, Jefferies raised its price target for Neurocrine Biosciences to $169, maintaining a Buy rating. Meanwhile, BMO Capital reiterated its Market Perform rating with a $124 price target, acknowledging the mixed results in higher doses of osavampator. Stifel also maintained its Buy rating with a $174 price target, highlighting the positive impact of the 1 mg dose in the trial. These updates reflect ongoing developments in Neurocrine Biosciences’ research and analyst evaluations.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.